相似文献
1
[Less vascular risk with rosuvastatin in elevated CRP].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):245.
2
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):216-7.
3
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1041; author reply 1041-2.
4
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1039; author reply 1041-2.
5
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1040; author reply 1041-2.
6
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1039; author reply 1041-2.
7
Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr. 2008 Nov-Dec;19(6):332-4, discussion 335.
8
JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
Cardiovasc J Afr. 2009 May-Jun;20(3):211.
9
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1038; author reply 1041-2. doi: 10.1056/NEJMc082574.
10
[JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
Lakartidningen. 2009;106(21-22):1460-1.
Zotero 插件